Argos Therapeutics to Present at the 13th Annual Needham Healthcare Conference

        Print
| Source: Argos Therapeutics, Inc.

DURHAM, N.C., April 1, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that the Company will be presenting at the 13th Annual Needham Healthcare Conference on April 8, 2014, at 2:20 p.m. Eastern Time. The conference will be held at The Westin Grand Central Hotel, in New York, NY.

A live audio webcast of the presentation can be accessed via the Investors section of the Company's website at www.argostherapeutics.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. A replay of the webcast will be available for 14 days following the presentation.

About Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The company also plans to report data from its Phase 2b trial of AGS-004 for the treatment of HIV in mid-2014. For more information about Argos Therapeutics, visit www.argostherapeutics.com.

Media:
Andrea Coan
Berry & Company Public Relations

(212) 253-8881

Investors:
Angeli Kolhatkar
Burns McClellan

(212) 213-0006